Cegedim Strategic Data (CSD) Provides Ailment-Specific Patient Information About Disease Onset, Treatment And Outcome

Main Category: Diabetes
Article Date: 03 Oct 2007 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Global pharmaceutical companies now can use country-specific information from Cegedim Strategic Data (CSD) to gauge how patients suffering from similar ailments react to a multitude of treatment regimens. The data, gathered from prescribers, tracks onset of diseases, as well as the specific medications used at various disease stages and in specific patient populations.

CSD's first syndicated Patient Diary Study (PDS) was conducted for the German diabetes market. Sixty-nine physicians reported 773 diabetes patient cases from January to March 2007. Among the results, the data showed that metformin, glimepiride and Lantus are significantly the most prescribed drugs for Type 2 diabetes patients (45 percent, 18 percent and 10 percent of the prescriptions, respectively).

CSD also conducted the same PDS study for the diabetes market in France. One-hundred physicians actively participated by submitting anonymous diabetic patient records from May to July 2007, totaling nearly 1,500 patient cases. Results show that there is a statistically significant difference among Type 2 diabetes patients in terms of treatment. While recent patients are prescribed more Biguanides, those patients diagnosed over five years ago are more often prescribed insulin and glitazone.

CSD is actively developing similar syndicated PDS studies for other therapeutic areas internationally. Custom PDS studies can also be deployed for any therapeutical class in 58 countries. Pharmaceutical companies then can use the data to track the impact of their marketing efforts among prescribers and determine what changes may be necessary.

This innovative PDS methodology includes a robust sample of specialists, nurses and/or general practitioners who participate in a panel and regularly provide real patient case information on a given therapeutical class. This information includes detailed treatment, prescription changing, patient profile, etc. The physicians receive an honorarium for their work.

The patient diary is divided into three main parts, all of which are crucial to understanding and monitoring how prescribers treat various patient types.

-- Prescription Market Share: Monitors the percentage of prescriptions by brand among GPs and specialists. The percentage can be predefined by individual brands or by therapeutic class.

-- Dynamic Segments: A particularly actionable benefit of PDS is the information illustrating prescription movements within the treatment algorithm (i.e. brand switch, combination therapy) and repeats.

-- Patient Profile: Compares prescribed treatment between different clusters of patients (i.e. most prescribed treatment for obese patients).

"This new offer comes on the heals of other recent new offerings, such as our Launch Kit Package, and our announcement of a partnership with a USA patient-level data provider," said Milena Brankova, Americas Regional Director of Cegedim Strategic Data. "The new PDS offering is one more sign of the serious attention CSD is paying to the US market and further servicing of our large base of US clients."

About Cegedim Strategic Data:

CSD is a leading Market Research company dedicated to the healthcare industry and operating in more than 58 countries. With over 35 years experience in the Pharmaceutical industry CSD (previously CAM, Thales, Zoom and Decisions Research) offers a comprehensive range of market research services and solutions to meet the needs of its customers, which include more than 50 global and 500 local Pharmaceutical companies. The capability to integrate primary market research with audited promotional data from PCPs, Specialists and Pharmacists, and merge it with longitudinal patient level data is what sets the company apart from its competition.

To learn more, please see our website: http://www.cegedimstrategicdata.com.

About CEGEDIM:

CEGEDIM has been developing exclusive databases and high value added software solutions since 1969. Established as the world's leading CRM provider for the life sciences industry with its Cegedim Dendrite business unit, CEGEDIM provides the world's largest pharmaceutical companies with vital support for successful Customer Relationship Management (CRM). Its Cegedim Strategic Data and Cegedim Customer Information business units are also dedicated to pharmaceutical companies and help them improve sales & marketing effectiveness thanks to the Group's strategic databases focused on the world drug market.

This expertise falls into the "Healthcare and strategic data" division of the CEGEDIM Group, which comprises the services specifically designed for pharmaceutical companies cited above and specific solutions dedicated to healthcare professionals (notably physicians and pharmacists in Europe) and health insurance providers.

The "Technologies and services" division capitalizes on the Group's technical skills in order to provide specific solutions to clients of various sectors, essentially in France.

CEGEDIM generated turnover of euro 541 million in 2006. Including Dendrite, the combined Group's pro forma 2006 revenue would amount to euro 877 million for a workforce of 7,500 and operations in more than 80 countries.

To learn more, please see our website: http://www.cegedim.com.

Cegedim Strategic Data
http://www.cegedim.com